Project Grant HT94252410992
Award Date
8/15/24
Completion Date
8/14/28
Dollars Obligated
$2.7M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The federal Project Grant award of $735,799.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is awarded to the University of Texas MD Anderson Cancer Center to support the project "INNOVATING BREAST CANCER RNA THERAPY: MECHANISMS AND PHARMACOGENETIC INHIBITORS". The project aims to conduct advanced biomedical research focused on transforming healthcare for military service members and the broader public,...
The U.S. Defense Health Agency has awarded a $7,001,734 Project Grant to The University of Texas MD Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The grant, which runs from August 15, 2024 to August 14, 2028, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to drive innovative cancer research and explore new approaches to prevention, diagnosis,...
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
The federal Project Grant award of $718,858.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support research led by the University of Texas MD Anderson Cancer Center to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The award, which runs from February 15, 2025 to February 14, 2028, will enable advanced cancer research focused on exploring innovative approaches to...
This federal Project Grant award of $2,351,546 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on September 1, 2024, supports a research initiative by the University of Texas MD Anderson Cancer Center to investigate "Epigenetic Mechanism and Targeting During Response to BRAF/Anti-EGFR Therapy in BRAF-Mutant Colorectal Cancers". The research aims to explore the underlying epigenetic...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,444,922.00 to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on a novel epigenetic determinant in metastatic prostate cancer. The award period is from September 15, 2024 to September 14, 2027. MD Anderson, a comprehensive cancer research and treatment center, will utilize this funding to carry out basic,...
The University of Texas MD Anderson Cancer Center was awarded a $1,635,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, titled "TARGETING A DRIVER KINASE, PCTK1, SYNERGIZES WITH FERROPTOSIS INDUCER TO COMBAT BREAST CANCER BRAIN METASTASIS", runs from June 1, 2025 to May 31, 2028. The grant supports advanced biomedical research initiatives focused on transforming healthcare for military...
This federal Project Grant award, with a total funding amount of $319,693.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research at The University of Texas Southwestern Medical Center (UT Southwestern) to investigate the mechanism of selective HIF-2 regulation of PTHrP and hypercalcemia in clear cell renal carcinoma. The research project aims to transform healthcare for military...
This Project Grant award, totaling $486,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports research conducted by the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to target PRMT5 in MTAP-loss melanoma. The project aims to transform health care for Service Members and the public through innovative and impactful cancer research, with a focus on...
The U.S. Department of Defense's Defense Health Agency has awarded a $1,882,607.00 Project Grant to The University of Texas MD Anderson Cancer Center (MD Anderson) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "LEVERAGING PROSTATE CANCERS' UNIQUE LIPID METABOLISM TO INDUCE THERAPEUTIC FERROPTOSIS," aims to conduct advanced biomedical research focused on transforming healthcare for military service members and the general...